



**MHRA**

10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

Prof C Butler  
UNIVERSITY OF OXFORD  
NUFFIELD DEPARTMENT OF PRIMARY CARE HEALTH SCIENCES,  
RADCLIFFE OBSERVATORY QUARTER, WOODSTOCK ROAD  
OXFORD  
OX2 6GG  
UNITED KINGDOM

07/04/2022

Dear Prof C Butler

**THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031**

Our Reference:	CTA 21584/0452/001-0004
IRAS ID:	1004274
Product:	Molnupiravir, Paxlovid
Protocol number:	PANORAMIC
Substantial Amendment Code Number:	Substantial Amendment 03

**NOTICE OF ACCEPTANCE OF AMENDMENT**

I am writing to inform you that the Licensing Authority, having reviewed your application in collaboration with the Research Ethics Committee (where applicable), accepts the proposed amendment to your clinical trial authorisation (CTA), received on 05/04/2022.

This amendment may therefore be made.

If applicable, you should ensure your trial details have been updated on the database where you have registered your trial.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

*You are reminded that from 1 January 2022 you will need to comply with the requirements specified in the following guidance, where applicable:*



**# Import of IMPs from listed countries to GB:**

<https://www.gov.uk/government/publications/importing-investigational-medicinal-products-into-great-britain-from-approved-countries>

**# Supply of IMPs to Northern Ireland:**

<https://www.gov.uk/guidance/supplying-investigational-medicinal-products-to-northern-ireland>

**# Substantial amendments to clinical trials:**

<https://www.gov.uk/guidance/guidance-on-substantial-amendments-to-a-clinical-trial>

***Any required substantial amendment to your Clinical Trial Authorisation should be submitted and approved as soon as possible and before 1 January 2022.***

Yours sincerely,

**Clinical Trials Unit  
MHRA**